Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis

Table 1

The characteristic of the 16 RCTs included in our study.

Study	Year		Age	Male (%)	Statin type	Dose (mg)	Duration (year)	Compliance
Keech et al.	1994	415	63	85	Simvastatin	20	3.4	93%
Salonen et al.	1995	424	57	100	Pravastatin	40	3.2	92%
Herd et al.	1997	429	59	81	Fluvastatin	40	2.5	90%
Patrick et al.	2002	1677	60	84	Fluvastatin	80	3.9	97%
Downs et al.	1998	6605	58	85	Lovastatin	30	5.2	99%
Shepherd et al.	1995	6595	55	100	Pravastatin	40	4.9	70%
Pedersen et al.	1994	4444	59	81	Simvastatin	27	5.4	99%
Tonkin	1998	9014	62	83	Pravastatin	40	6.1	87%
Sacks et al.	1996	4159	59	86	Pravastatin	40	5.0	90%
Shepherd et al.	2002	5804	75	48	Pravastatin	40	3.2	86%
Armitage et al.	2009	20536	64	83	Simvastatin	40	5.0	85%
Bays et al.	2004	1526	55	48	Simvastatin	60	0.25	90%
Baigent et al.	2005	448	53	79	Simvastatin	20	1.0	80%
Furberg et al.	1994	919	62	52	Lovastatin	30	2.8	95%
Newman et al.	2008	2838	62	68	Atorvastatin	10	3.9	90%
Bradford et al.	1991	8245	56	59	Lovastatin	80	1.0	97%